Medicine-induced Cardiac Hemodialysis on COVID-19

NCT05711810 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-02-03

No results posted yet for this study

Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Conditions

  • Severe Acute Respiratory Syndrome-related Coronavirus
  • Renal Dialysis
  • Vaccines
  • Myocarditis Allergic
  • Infection Viral

Interventions

DRUG

Nifedipine 30 MG

Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.

DIAGNOSTIC_TEST

Kangzhu BPCB0A-3A

The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.

BEHAVIORAL

Low Mobility

The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.

DRUG

Enalapril Maleate 10Mg Tab

The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.

DRUG

Lansoprazole 30Mg Ec Cap

The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.

DRUG

Metoprolol Succinate

Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.

DIETARY_SUPPLEMENT

Coenzyme Q10

200 mg per day is used for supplement with the cardiac interventions.

DIETARY_SUPPLEMENT

d-alpha tocopherol acetate

The 268 mg twice per day dietary healthcare is the patient's usual daily use.

DIETARY_SUPPLEMENT

Omega-3

The 900 mg twice per day dietary healthcare is the patient's usual daily use.

DRUG

Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

Duloxetine hydrochloride is used for the patient's neurodiverse conditions.

DRUG

Superoxide Dismutase

Superoxide Dismutase is used to substitute the missing of antiviral drugs.

Sponsors & Collaborators

  • Yang I. Pachankis

    lead INDIV

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2023-01-10
Completion
2023-01-12
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05711810 on ClinicalTrials.gov